Click Here to Go Directly to the Story




U.S. EDITION
Full Table of Contents
 Cover Story
Up Front
Readers Report
Corrections & Clarifications
Books
Technology & You
Economic Viewpoint
Business Outlook
News: Analysis & Commentary
In Business This Week

Washington Outlook
Science & Technology
Information Technology
The Corporation
Legal Affairs
Finance
Developments to Watch
Management
BusinessWeek Investor
Dividends

The Barker Portfolio
Inside Wall Street
Figures of the Week
Editorials


INTERNATIONAL EDITIONS
International -- Int'l Cover Story
International -- Readers Report
International -- Asian Business
International -- European Business
International -- Latin America
International -- Int'l Figures of the Week
ONLINE FEATURES Book Reviews BW Video Columnists Interactive Gallery Newsletters Past Covers Philanthropy Podcasts Special Reports BLOGS Auto Beat Bangalore Tigers Blogspotting Brand New Day Byte of the Apple Economics Unbound Eye on Asia Fine On Media Green Biz Hot Property Investing Insights Management IQ NEXT: Innovation NussbaumOnDesign Tech Beat Working Parents TECHNOLOGY J.D. Power Ratings Product Reviews Tech Stats Wildstrom: Tech Maven AUTOS Home Page Auto Reviews Classic Cars Car Care & Safety Hybrids INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip INVESTING Investing: Europe Annual Reports BW 50 S&P Picks & Pans Stock Screeners Free S&P Stock Report SCOREBOARDS Hot Growth 100 Mutual Funds Info Tech 100 S&P 500 B-SCHOOLS Undergrad Programs MBA Blogs MBA Profiles MBA Rankings Who's Hiring Grads


DECEMBER 23, 2002

Corrections & Clarifications

  STORY TOOLS
Printer-Friendly Version
E-Mail This Story

On This Page
"An ache at Amgen?" (Science & Technology, Dec. 9, 2002)

"An ache at Amgen?" (Science & Technology, Dec. 9, 2002)

 "An ache at Amgen?" (Science & Technology, Dec. 9) incorrectly stated that the Amgen drug Enbrel is derived in part from hamster proteins. Although Enbrel is grown in hamster cells, it is a fully human protein.



Back to Top


TODAY'S MOST POPULAR STORIES

  1. Apple's Schiller Defends iPhone App Approval Process
  2. Developers Look Past Apple's Jammed iPhone App Store
  3. Wall Street: Is It Good to Apologize for Greed?
  4. Picks of the Week: Intel, RIM, Wells Fargo
  5. Cisco's Extreme Ambitions

Get Free RSS Feed >>
  MARKET INFO

Portfolio Service Update

Stock Lookup

Enter name or ticker



Copyright 2002, by The McGraw-Hill Companies Inc. All rights reserved.
Terms of Use | Privacy Policy

Media Kit | Special Sections | MarketPlace | Knowledge Centers
McGraw-Hill Cos.